|
|
Post by brotherm1 on Sept 19, 2016 13:59:48 GMT -5
|
|
|
|
Post by nylefty on Sept 19, 2016 14:24:31 GMT -5
Talk about misinformation. A reader who was unfamiliar with the Afrezza story would come away thinking that the black box warning came after Afrezza was already on the market. Notice that the article falsely says that Sanofi pulled out of the Afrezza deal because of the warning. It also says that doctors are "not willing to prescribe Afrezza" because of the warning, when we all know that it's far more complicated then that. The company did receive approval from the Federal Drug Administration (FDA), however it was given a black-box warning for possible constriction of airways following its use. Due to this factor, doctors are not willing to prescribe Afrezza to patients. This has proved to be a major obstacle for MannKind, and the company has trended lower since this decision.
Additionally, this FDA ruling caused MannKind's major partner, Sanofi-Aventis (NYSE: SNY), to walk away from its partnership to commercialize Afrezza.
|
|
|
|
Post by mannmade on Sept 19, 2016 14:53:31 GMT -5
It also said Sanofi spent a billion dollars on AFREZZA. Now that's what I would call fuzzy math... Must be including all of the milestone payments we never saw...
|
|
